Phaseline

Companies › Priothera SAS

Priothera SAS: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
mocravimod
Sphingosine 1-phosphate receptor Edg-1 agonist
S1PR1Phase 3Adult Acute Myeloid LeukemiaMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05429632mocravimodPhase 3Adult Acute Myeloid LeukemiaOncologyMay 2027

Targets

S1PR1 (1)

Companies with the same targets

Novartis Viatris Innovation Boehringer Ingelheim Vanda Pharmaceuticals Bristol-Myers Squibb Pfizer Aptabio Therapeutics

Companies built like this

LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company Quercis Pharma ABX advanced biochemical compounds

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.